Compared to pan-PI3K inhibitors, isotype-specific inhibitors exhibit less off-target toxicity because they are specific to the tumor type; thus, isotype-specific inhibitors can be administered at higher doses and are more effective.202 Alpelisib (BYL-719) and taselisib (GDC-0032) are representative homospecific inhibitors. Here, PIK3CB is linked to neoplasm.